Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy
Cornelia Hutmacher, Dario Neri
Advanced Drug Delivery Reviews (2018) Vol. 141, pp. 67-91
Closed Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Antibody Structure and Function: The Basis for Engineering Therapeutics
Mark L. Chiu, Dennis R. Goulet, A. Teplyakov, et al.
Antibodies (2019) Vol. 8, Iss. 4, pp. 55-55
Open Access | Times Cited: 479
Emerging new therapeutic antibody derivatives for cancer treatment
Shijie Jin, Yanping Sun, Liang Xiao, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 319
Thermal immuno-nanomedicine in cancer
Zhe Yang, Di Gao, Jing Zhao, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 2, pp. 116-134
Closed Access | Times Cited: 141
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Linghui Qian, Xuefen Lin, Xue Gao, et al.
Chemical Reviews (2023) Vol. 123, Iss. 12, pp. 7782-7853
Closed Access | Times Cited: 65
Revisiting the role of IL-27 in obesity-related metabolic diseases: safeguard or perturbation?
Jinyang An, Dzgoeva Fu, Ximei Chen, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 2
Antibody–Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity
Dario Neri
Cancer Immunology Research (2019) Vol. 7, Iss. 3, pp. 348-354
Open Access | Times Cited: 127
Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation
Patrizia Murer, Dario Neri
New Biotechnology (2019) Vol. 52, pp. 42-53
Open Access | Times Cited: 83
Engineering Strategies for Immunomodulatory Cytokine Therapies: Challenges and Clinical Progress
Ivan S. Pires, Paula T. Hammond, Darrell J. Irvine
Advanced Therapeutics (2021) Vol. 4, Iss. 8
Open Access | Times Cited: 73
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
Alfredo Quijano‐Rubio, M. Aladdin Bhuiyan, Huilin Yang, et al.
Nature Biotechnology (2022) Vol. 41, Iss. 4, pp. 532-540
Open Access | Times Cited: 51
The present and future of immunocytokines for cancer treatment
Dennis Y. Gout, Lotte S. Groen, Marjolein van Egmond
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 10
Open Access | Times Cited: 40
Recent advances and future perspectives in the therapeutics of prostate cancer
Ganji Lakshmi Varaprasad, Vivek Gupta, K. Satya Prasad, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 26
The JAK-STAT pathway: from structural biology to cytokine engineering
You Lv, Jianxun Qi, Jeffrey J. Babon, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 13
Plant-derived Pembrolizumab in conjugation with IL-15Rα-IL-15 complex shows effective anti-tumor activity
Kaewta Rattanapisit, Pipob Suwanchaikasem, Christine Joy I. Bulaon, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0316790-e0316790
Open Access | Times Cited: 1
Advances in antibody engineering for rheumatic diseases
Anja Schmid, Dario Neri
Nature Reviews Rheumatology (2019) Vol. 15, Iss. 4, pp. 197-207
Closed Access | Times Cited: 56
Cytokine engineering for targeted cancer immunotherapy
Lucia Bonati, Li Tang
Current Opinion in Chemical Biology (2021) Vol. 62, pp. 43-52
Open Access | Times Cited: 55
Modular Chemical Construction of IgG-like Mono- and Bispecific Synthetic Antibodies (SynAbs)
Fabien Thoreau, Péter A. Szijj, Michelle K. Greene, et al.
ACS Central Science (2023) Vol. 9, Iss. 3, pp. 476-487
Open Access | Times Cited: 20
Next-generation anti-PD-L1/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity
Wenqiang Shi, Nan Liu, Zexin Liu, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 5, pp. 101531-101531
Open Access | Times Cited: 6
The antibody‐based delivery of interleukin‐12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune checkpoint inhibitors
Emanuele Puca, Philipp Probst, Marco Stringhini, et al.
International Journal of Cancer (2019) Vol. 146, Iss. 9, pp. 2518-2530
Open Access | Times Cited: 47
Alternative Vascularization Mechanisms in Tumor Resistance to Therapy
Dorina Belotti, Denise Pinessi, Giulia Taraboletti
Cancers (2021) Vol. 13, Iss. 8, pp. 1912-1912
Open Access | Times Cited: 37
Biomaterials‐Based Delivery of Therapeutic Antibodies for Cancer Therapy
Qian‐Ni Ye, Yue Wang, Song Shen, et al.
Advanced Healthcare Materials (2021) Vol. 10, Iss. 11
Closed Access | Times Cited: 37
Engineered antibody fusion proteins for targeted disease therapy
Aliyah B. Silver, Elissa K. Leonard, Joseph R. Gould, et al.
Trends in Pharmacological Sciences (2021) Vol. 42, Iss. 12, pp. 1064-1081
Open Access | Times Cited: 37
Nanomaterials for Targeting Liver Disease: Research Progress and Future Perspectives
Yinghua Wu, Junfeng Zhang, Wen He, et al.
Nano Biomedicine and Engineering (2023) Vol. 15, Iss. 2, pp. 199-224
Open Access | Times Cited: 13
Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment
Lin Feng, Shenyi Yin, Zijian Zhang, et al.
Cell (2024)
Closed Access | Times Cited: 5
Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice
Carmine Carbone, R. De Luca, Emanuele Puca, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
Developing anti-TDE vaccine for sensitizing cancer cells to treatment and metastasis control
Stephene S. Meena, Benson Kiprono Kosgei, Geofrey F. Soko, et al.
npj Vaccines (2025) Vol. 10, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top